For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

EAY131

Trial Overview

Official Title

This MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

Study Purpose

To evaluate the proportion of patients with objective response to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

Diagnosis

Patients had a sample of tumor tested by a MATCH-designated lab. The test showed the tumor has a gene change, or mutation targeted by one or more of the drugs used in this study.

Eligibility

Patient has cancer that has become worse following treatment, or no standard therapy exists for that type of cancer.

Patient must have actionable mutation of interest determined by molecular profiling.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Tissue is sent for molecular testing and if an actionable mutation is identified patients are placed in various substudies.  Treatment in substudies is based on specific mutation present.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Not Applicable
Methodist Health System Trial Code
EAY131
Related Specialties